Domov › Rak pljuč › Michigan › Ann Arbor
Klinične študije za Rak pljuč v Ann Arbor, MI
23 študij za Rak pljuč išče udeležence na lokacijah v Ann Arbor in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Vključevanje udeležencevFaza 3
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi stran
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18 mi stran
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Vključevanje udeležencevFaza 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi stran
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
- in še 4
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Vključevanje udeležencevFaza 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi stran
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
- in še 4
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi stran
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
- in še 4
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Vključevanje udeležencevFaza 3
- University of Michigan Rogel Cancer Center, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi stran
- in še 2
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Vključevanje udeležencevFaza 3
- Trinity Health Ann Arbor Hospital, Ann Arbor
A Registry for People With Lung Cancer
Vključevanje udeležencevOpazovalna študija
- University of Michigan (Data Collection Only), Ann Arbor
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Vključevanje udeležencevFaza 2/3
- Local Institution - 0418, Ann Arbor
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Vključevanje udeležencevFaza 1/2
- University of Michigan Medical School Rogel Cancer Center, Ann Arbor
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- University of Michigan, Ann Arbor
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
Vključevanje udeležencevFaza 3
- University of Michigan, Ann Arbor
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
- Chelsea Hospital, Chelsea · 15 mi stran
- in še 3
Gilteritinib for the Treatment of ALK NSCLC
Vključevanje udeležencevFaza 1
- University of Michigan Comprehensive Cancer Center, Ann Arbor
Prediction Augmented Screening Initiative
Vključevanje udeležencev
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi stran
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
- in še 4
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2/3
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi stran
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18 mi stran
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi stran
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi stran
- in še 4
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Vključevanje udeležencevFaza 1/2
- University of Michigan, Ann Arbor
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Vključevanje udeležencev
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 1/2
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients
Vključevanje udeležencev
- University of Michigan Comprehensive Cancer Center, Ann Arbor
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Ann Arbor
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- University of Michigan, Ann Arbor
Študije za Rak pljuč v drugih mestih
- Houston, TX78 študij
- Boston, MA62 študij
- New York City, NY60 študij
- Los Angeles, CA45 študij
- Arlington, VA41 študij
- Washington, DC41 študij
- Chicago, IL41 študij
- Baltimore, MD40 študij
- Nashville, TN40 študij
- St. Louis, MO39 študij
- Columbus, OH37 študij
- Philadelphia, PA36 študij
Druge študije v Ann Arbor
- Rak dojke27 študij
- Rak prostate27 študij
- Nemalicelični pljučni rak26 študij
- Rak (vse vrste)25 študij
- Kolorektalni rak23 študij
- Srčno popuščanje22 študij
- Akutna mieločna levkemija17 študij
- Srčno-žilne bolezni16 študij
- Rak trebušne slinavke14 študij
- Melanom12 študij
- Možganska kap12 študij
- Ploščatocelični karcinom glave in vratu12 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.